| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Gwo Xi Stem Cell Applied Technology Co. , Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$32.30 |
| 52 Week High | NT$55.80 |
| 52 Week Low | NT$28.60 |
| Beta | 0 |
| 1 Month Change | 11.00% |
| 3 Month Change | -4.01% |
| 1 Year Change | -26.84% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -29.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6704 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 7.7% | -1.6% | -2.3% |
| 1Y | -26.8% | -22.6% | 27.2% |
Return vs Industry: 6704 underperformed the TW Biotechs industry which returned -22.6% over the past year.
Return vs Market: 6704 underperformed the TW Market which returned 27.2% over the past year.
Price Volatility
| 6704 volatility | |
|---|---|
| 6704 Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6704 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6704's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | n/a | www.gwoxi.com.tw |
Gwo Xi Stem Cell Applied Technology Co. , Ltd. develops stem cell medicines for patients with unmet medical needs. The company’s products under development include GXHPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke.
Gwo Xi Stem Cell Applied Technology Co. , Ltd Fundamentals Summary
| 6704 fundamental statistics | |
|---|---|
| Market cap | NT$3.10b |
| Earnings (TTM) | -NT$82.45m |
| Revenue (TTM) | NT$160.47m |
19.3x
P/S Ratio-37.6x
P/E RatioIs 6704 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6704 income statement (TTM) | |
|---|---|
| Revenue | NT$160.47m |
| Cost of Revenue | NT$39.96m |
| Gross Profit | NT$120.51m |
| Other Expenses | NT$202.96m |
| Earnings | -NT$82.45m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 75.10% |
| Net Profit Margin | -51.38% |
| Debt/Equity Ratio | 86.0% |
How did 6704 perform over the long term?
See historical performance and comparison